SCHEMBL16611103

SCHEMBL16611103

O=c1[nH]cc(Cl)c2c1c(-c1ccc(N3CCOCC3)cc1)nn2-c1c(F)cccc1F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.43
ALDH1A1 P00352 2/20 0.43
HPGD P15428 1/20 0.43
PDGFRB P09619 1/20 0.43
CDK2 P24941 5/20 0.41
CCNA2 P20248 3/20 0.41
CNR2 P34972 1/20 0.40
ROCK1 Q13464 2/20 0.38
GSK3B P49841 2/20 0.38
MAPT P10636 1/20 0.37
NTRK1 P04629 1/20 0.37
TNKS O95271 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C9 P11712 1/20 0.37
TNKS2 Q9H2K2 1/20 0.37
ZAP70 P43403 1/20 0.37
ABCB1 P08183 1/20 0.36
CDK1 P06493 1/20 0.35
CDK4 P11802 1/20 0.35
CCNB1 P14635 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL16611325 0.99 KDM4E (0.43) KDM4EALDH1A1HPGDPDGFRBCDK2
SCHEMBL16611193 0.96 PDGFRB (0.42) KDM4EALDH1A1HPGDPDGFRBCDK2
SCHEMBL16610794 0.90 ALDH1A1 (0.34) KDM4EALDH1A1HPGDPDGFRBCDK2
SCHEMBL16611152 0.90 PDGFRB (0.41) KDM4EALDH1A1HPGDPDGFRBCDK2
SCHEMBL16611220 0.90 PDGFRB (0.41) KDM4EALDH1A1HPGDPDGFRBCDK2
SCHEMBL16611412 0.90 PDE3B (0.43) KDM4EALDH1A1HPGDMAPTCYP3A4
SCHEMBL16610919 0.89 JAK2 (0.36) KDM4EALDH1A1HPGDPDGFRBCDK2
SCHEMBL16610669 0.89 CNR2 (0.48) CNR2NTRK1
SCHEMBL16610943 0.89 CYP2A13 (0.42) KDM4EALDH1A1HPGDNTRK1TNKS
SCHEMBL16610918 0.89 KDM4E (0.33) KDM4EALDH1A1HPGDPDGFRBCDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160251352-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2016-09-01 US disclosed
US-20160251352-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2016-09-01 US disclosed
US-20160251352-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2016-09-01 US disclosed
US-9371320-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-06-21 US disclosed
US-20150141406-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-05-21 US disclosed
US-20150141406-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-05-21 US disclosed
US-20150141406-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-05-21 US disclosed
EP-2857400-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2015-04-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160251352-A1 HETEROCYCLIC COMPOUND JAK2, JAK1, STAT3 KDM4E 456/4885ALDH1A1 3511/4885HPGD 1854/4885
US-20150141406-A1 HETEROCYCLIC COMPOUND JAK2, JAK1, STAT3 KDM4E 456/4885ALDH1A1 3511/4885HPGD 1854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.